|
1
|
Jahn KA, Su Y and Braet F: Multifaceted
nature of membrane microdomains in colorectal cancer. World J
Gastroenterol. 17:681–990. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adachi Y, Yamamoto H, Ohashi H, Endo T,
Carbone DP, Imai K and Shinomura Y: A candidate targeting molecule
of insulin-like growth factor-I receptor for gastrointestinal
cancers. World J Gastroenterol. 16:5779–5789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baserga R: The insulin-like growth factor
I receptor: A key totumor growth? Cancer Res. 55:249–252.
1995.PubMed/NCBI
|
|
4
|
Yu H and Rohan T: Role of the insulin-like
growth factor family in cancer development and progression. J Natl
Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodon J, De Santos V, Ferry RJ Jr and
Kurzrock R: Early drug development of inhibitors of the
insulin-like growth factor-Ireceptor pathway: Lessons from the
first clinical trials. Mol Cancer Ther. 7:2575–2588. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y,
Dong J, Chen F, Wang X and Shen H: Phenotypes and genotypes of
insulin-like growth factor 1, IGF-binding protein-3 and cancer
risk: Evidence from 96 studies. Eur J Hum Genet. 17:1668–1675.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rinaldi S, Cleveland R, Norat T, Biessy C,
Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C,
et al: Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk:
Results from the EPIC cohort, plus a meta-analysis of prospective
studies. Int J Cancer. 126:1702–1715. 2010.PubMed/NCBI
|
|
8
|
Dunn SE, Kari FW, French J, Leininger JR,
Travlos G, Wilson R and Barrett JC: Dietary restriction reduces
insulin-like growth factor I levels, which modulates apoptosis,
cell proliferation, and tumor pogression in p53-deficient mice.
Cancer Res. 57:4667–4672. 1997.PubMed/NCBI
|
|
9
|
Wu Y, Yakar S, Zhao L, Hennighausen L and
LeRoith D: Circulating insulin-like growth factor-I levels regulate
colon cancer growth and metastasis. Cancer Res. 62:1030–1035.
2002.PubMed/NCBI
|
|
10
|
Blais L, Desgagne´ A and LeLorier J:
3-Hydroxy-3-methylglutaryl coenzymeA reductase inhibitors and the
risk of cancer: A nested case-control study. Arch Intern Med.
160:2363–2368. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graaf MR, Beiderbeck AB, Egberts AC,
Richel DJ and Guchelaar HJ: The risk of cancer in users of statins.
J Clin Oncol. 22:2388–2394. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gallagher EJ and LeRoith D: The
proliferating role of insulin and insulin-like growth factors in
cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reinmuth N, Fan F, Liu W, Parikh AA,
Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE and Ellis
LM: Impact of insulin-like growth factor receptor-I function on
angiogenesis, growth, and metastasis of colon cancer. Lab Invest.
82:1377–1389. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
LeRoith D and Roberts CT: The insulin-like
growth factor system and cancer. Cancer Lett. 195:127–137. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shibata T, Tamura M, Kabashima N, Serino
R, Tokunaga M, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y,
Takeuchi M, et al: Fluvastatin attenuates IGF-1-induced ERK1/2
activation and cell proliferation by mevalonic acid depletion in
human mesangial cells. Life Sci. 84:725–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sekine Y, Furuya Y, Nishii M, Koike H,
Matsui H and Suzuki K: Simvastatin inhibits the proliferation of
human prostate cancer PC-3 cells via down-regulation of the
insulin-like growth factor 1 receptor. Biochem Biophys Res Commun.
372:356–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yavari K, Taghikhani M, Maragheh MG,
Mesbah-Namin SA and Babaei MH: Knockdown of IGF-IR by RNAi inhibits
SW480 colon cancer cells growth in vitro. Arch Med Res. 40:235–240.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wortzel I and Seger R: The ERK cascade:
Distinct functions within various subcellular organelles. Genes
Cancer. 2:195–209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chung J, Kubota H, Ozaki Y, Uda S and
Kuroda S: Timing-dependent actions of NGF required for cell
differentiation. PLoS One. 5:e90112010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen XJ, Wang HB, Ma XQ and Chen JH:
β,β-Dimethylacrylshikonin induces mitochondria dependent apoptosis
through ERK pathway in human gastric cancer SGC-7901 cells. PLoS
One. 7:e417732012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim MJ, Park IJ, Yun H, Kang I, Choe W,
Kim SS and Ha J: AMP-activated protein kinase antagonizes
pro-apoptotic extracellular signal-regulated kinase activation by
inducing dual-specificity protein phosphatases in response to
glucose deprivation in HCT116 carcinoma. J Biol Chem.
285:14617–14627. 2010. View Article : Google Scholar : PubMed/NCBI
|
